Dr. Barry Dworkin

Prostate cancer: New combination therapy could reduce progression risk

Medical Mythbusting Commentary for March 27, 2023

Source:
Prostate cancer: New combination therapy could reduce progression risk

Reference:
TALAPRO-2 Supports First-Line Talazoparib/Enzalutamide in All-Comers With mCRPC

Related posts:

  1. Clinical relevance of drug to slow low grade prostate cancer unclear
  2. Prostate cancer surgery results no different from not doing the surgery: study
  3. "New" PSA guidelines from Prostate Cancer Canada will cause more harm than good and is not supported by evidence
  4. New class of prostate cancer drug treatment to start clinical trials